Initial data from INSIGHT-003 trial treating patients with various solid tumours with triple combination therapy of efti, anti-PD-1 therapy, and chemotherapy to be discussed at SITC
Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease, will announce first interim data from the INSIGHT-003 clinical trial in a poster presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2022, which is taking place in person in Boston, US and virtually from 8 to 12 November 2022. A Trial in Progress poster on the phase IIb TACTI-003 trial will also be presented.
For more information, download the attached PDF.
Download this document
